Cochrane review finds intermittent fasting no better for weight loss

A new Cochrane review of 22 clinical trials shows that intermittent fasting does not lead to greater weight loss than standard diet advice for overweight or obese adults. The analysis, involving nearly 2,000 participants, challenges the popularity of fasting methods amid rising global obesity rates. Researchers emphasize the need for more long-term studies and personalized approaches.

Obesity has become a pressing public health issue, with the World Health Organization noting that adult obesity rates have tripled since 1975. In 2022, approximately 2.5 billion adults were overweight, including 890 million living with obesity.

Intermittent fasting, popularized through social media and wellness trends, involves strategies like alternate-day fasting, periodic fasting, and time-restricted feeding. However, a Cochrane review published in 2026 examined 22 randomized clinical trials with 1,995 adults from regions including North America, Europe, China, Australia, and South America. Most trials lasted up to one year.

The review found no clinically meaningful difference in weight loss between intermittent fasting and conventional diet advice or no intervention at all. Side effects were not consistently reported, limiting assessments of risks. The studies primarily involved white participants from high-income countries, highlighting gaps in research for diverse populations.

"Intermittent fasting just doesn't seem to work for overweight or obese adults trying to lose weight," stated Luis Garegnani, lead author from the Universidad Hospital Italiano de Buenos Aires Cochrane Associate Centre. He added, "Intermittent fasting may be a reasonable option for some people, but the current evidence doesn't justify the enthusiasm we see on social media."

The lack of long-term data poses challenges, as obesity is a chronic condition. "Obesity is a chronic condition. Short-term trials make it difficult to guide long-term decision-making for patients and clinicians," Garegnani noted.

Senior author Eva Madrid from the Cochrane Evidence Synthesis Unit Iberoamerica remarked, "With the current evidence available, it's hard to make a general recommendation. Doctors will need to take a case-by-case approach when advising an overweight adult on losing weight."

The authors suggest results may vary by factors such as sex, age, ethnicity, medical conditions, or eating behaviors, calling for further research in low- and middle-income countries.

Articoli correlati

A medical professional reviewing a WHO report on GLP-1 weight loss drugs, surrounded by injectable pens and a scale, illustrating confirmed benefits and lingering long-term questions.
Immagine generata dall'IA

WHO-commissioned Cochrane reviews confirm GLP-1 drugs aid weight loss, but long-term questions remain

Riportato dall'IA Immagine generata dall'IA Verificato

Three new Cochrane reviews conclude that tirzepatide, semaglutide and liraglutide produce clinically meaningful weight loss in adults with obesity, while evidence on long‑term safety, broader outcomes and equitable access remains limited. The findings will inform forthcoming World Health Organization guidance on obesity treatment.

A new review of studies suggests that intermittent fasting offers no significant advantage over traditional dieting or no intervention for weight loss among overweight or obese adults. Researchers analyzed data from 22 trials involving nearly 2,000 participants. While the approach remains popular, experts highlight limitations in the evidence.

Riportato dall'IA

A new study challenges the hype around intermittent fasting, finding that limiting eating to an eight-hour window does not improve metabolic health if calorie intake remains the same. Researchers from German institutions observed shifts in the body's internal clocks but no changes in insulin sensitivity or cardiovascular markers. The results suggest that calorie control, rather than meal timing alone, drives potential health gains.

A novel weight management initiative called PATHWEIGH, developed by endocrinologist Leigh Perreault, has successfully stopped population-level weight gain in primary care settings across Colorado. Tested in a large-scale trial involving over 274,000 patients, the program increased access to obesity treatments and is now attracting interest from health systems nationwide. Published results show a 0.58 kg reduction in average weight gain over 18 months, marking a significant public health advancement.

Riportato dall'IA

A new study from University of Utah Health reveals that while the ketogenic diet prevents weight gain in mice, it leads to serious metabolic problems like fatty liver disease and impaired blood sugar control over time. Male mice experienced the most severe effects, including liver damage. The findings, published in Science Advances, question the diet's long-term safety for metabolic health.

A prespecified analysis of the SELECT trial reports that weekly semaglutide lowered the risk of heart attacks and strokes by about 20% in adults with established cardiovascular disease and overweight or obesity—even when little weight was lost—suggesting benefits beyond slimming alone.

Riportato dall'IA Verificato

A four-year study from the University of Southern California finds that greater intake of ultra-processed foods is linked to higher odds of prediabetes and early insulin resistance in young adults aged 17 to 22.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta